WO2009158446A3 - Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof - Google Patents

Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof Download PDF

Info

Publication number
WO2009158446A3
WO2009158446A3 PCT/US2009/048547 US2009048547W WO2009158446A3 WO 2009158446 A3 WO2009158446 A3 WO 2009158446A3 US 2009048547 W US2009048547 W US 2009048547W WO 2009158446 A3 WO2009158446 A3 WO 2009158446A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbamoyl
methylpyrrolo
phosphonooxy
triazin
methylphenyl
Prior art date
Application number
PCT/US2009/048547
Other languages
French (fr)
Other versions
WO2009158446A2 (en
Inventor
Michael Galella
Jack Z. Gougoutas
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of WO2009158446A2 publication Critical patent/WO2009158446A2/en
Publication of WO2009158446A3 publication Critical patent/WO2009158446A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention generally relates to crystalline forms of ( ( ( (4- ( (5- (cyclopropyl carbamoyl) -2-methylphenyl)amino) -5-methylpyrrolo [2,1-f ] [1, 2,4] triazin-6-yl) carbonyl) (propyl) carbamoyl )oxy) methyl (4- (phosphonooxy) phenyl) acetate. The present invention also generally relates to a pharmaceutical composition comprising said crystalline form, as well of methods of obtaining and using the crystalline form for the treatment of inflammatory-associated diseases or disorders.
PCT/US2009/048547 2008-06-25 2009-06-25 Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof WO2009158446A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7536608P 2008-06-25 2008-06-25
US61/075,366 2008-06-25

Publications (2)

Publication Number Publication Date
WO2009158446A2 WO2009158446A2 (en) 2009-12-30
WO2009158446A3 true WO2009158446A3 (en) 2010-02-25

Family

ID=41059806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/048547 WO2009158446A2 (en) 2008-06-25 2009-06-25 Crystalline forms of ((((4-((5-(cyclopropylcarbamoyl)-2-methylphenyl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbonyl)(propyl)carbamoyl)oxy)methyl (4-(phosphonooxy)phenyl)acetate, method of preparation and use thereof

Country Status (1)

Country Link
WO (1) WO2009158446A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ762856A (en) 2017-10-05 2020-07-31 Fulcrum Therapeutics Inc P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213300A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070213300A1 (en) * 2006-03-07 2007-09-13 Bristol-Myers Squibb Company Pyrrolotriazine aniline prodrug compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
WO2009158446A2 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
WO2010048332A3 (en) Compounds for treating ophthalmic diseases and disorders
WO2009005794A3 (en) Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders
WO2007017135A3 (en) Process for the preparation of olmesartan medoxomil
WO2010066684A3 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
EP2940017A3 (en) Processes for making compounds useful as inhibitors of atr kinase
WO2006131491A8 (en) Polymorphs of ethyl 3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate
UA110089C2 (en) Normal;heading 1;heading 2;heading 3;ALKOXY COMPOUNDS FOR FOR TREATING NEURODEGENERATIVE DISEASES
WO2010003313A8 (en) Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
WO2008076392A3 (en) Compounds useful as protein kinase inhibitors
WO2012162254A8 (en) Inhibitors of lrrk2 kinase activity
WO2008000483A3 (en) Phenol derivatives for the treatment of respiratory diseases
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2006094763A8 (en) 3,4,5-substituted piperidine compounds
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
WO2007099553A3 (en) 1,3-dioxane carboxylic acids
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2007006534A3 (en) Piperidine derivatives useful in the diagnostic and therapeutic treatment of diseases depending on renin activity
IN2012DN03391A (en)
WO2006050472A3 (en) Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous and -phosphinic acids
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2008117305A3 (en) A novel process for preparing pregabalin and its acid addition salts
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
EP2772481A8 (en) Novel compound as kcnq potassium channel agonist, preparation method therefor and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09770979

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09770979

Country of ref document: EP

Kind code of ref document: A2